Lyme Disease: Has Big Pharma Stopped The Clock On A Cure?
Though vastly underreported, new cases of Lyme in the US total more than 300,000 a year; its incidence now exceeds infections for far more visible conditions like HIV. A higher profile for Lyme is hobbled by a slow and distorted institutional response, especially among clinicians who disagree on whether Lyme is one disease or a complex constellation of many – much like cancer, but without the commitment.
You may also be interested in...
Trek Therapeutics, a three-year old biotech founded by a group of virology veterans, is testing the conventional wisdom in seeking to carve out a potential $17 billion business in the hotly contested hepatitis C space.
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
In this latest edition of the Lab Links series on notable figures responsible for major advances in drug discovery, In Vivo talks to Harvard Medical School professor and biologist Timothy Springer on his 50-year record as an academic scientist, business entrepreneur and philanthropist. His latest venture is being co-founder – and principal funder – of the independent non-profit Institute for Protein Innovation, an institution designed to fill a critical niche in open-source biomedical research.